Navigation Links
Mini-Organ Would Mimic Pancreas to Treat Type 1 Diabetes
Date:3/5/2013

By Serena Gordon
HealthDay Reporter

TUESDAY, March 5 (HealthDay News) -- A new bioengineered, miniature organ dubbed the BioHub might one day offer people with type 1 diabetes freedom from their disease.

In its final stages, the BioHub would mimic a pancreas and act as a home for transplanted islet cells, providing them with oxygen until they could establish their own blood supply. Islet cells contain beta cells, which are the cells that produce the hormone insulin. Insulin helps the body metabolize the carbohydrates found in foods so they can be used as fuel for the body's cells.

The BioHub also would provide suppression of the immune system that would be confined to the area around the islet cells, or it's possible each islet cell might be encapsulated to protect it against the autoimmune attack that causes type 1 diabetes.

The first step, however, is to load islet cells into the BioHub and transplant it into an area of the abdomen known as the omentum. These trials are expected to begin within the next year or year and a half, said Dr. Luca Inverardi, deputy director of translational research at the Diabetes Research Institute at the University of Miami, where the BioHub is being developed.

Dr. Camillo Ricordi, the director of the institute, said the project is very exciting. "We're assembling all the pieces of the puzzle to replace the pancreas," he said.

"Initially, we have to go in stages, and clinically test the components of the BioHub," he said. "The first step is to test the scaffold assembly that will work like a regular islet cell transplant."

The Diabetes Research Institute already successfully treats type 1 diabetes with islet cell transplants into the liver.

In type 1 diabetes, an autoimmune disease, the body's immune system mistakenly attacks and destroys the beta cells contained within islet cells. This means someone with type 1 diabetes can no longer produce the insulin they need to get sugar (glucose) to the body's cells, so they must replace the lost insulin. This can be done only through multiple daily injections or with an insulin pump via a tiny tube inserted under the skin and changed every few days.

Although islet cell transplantation has been very successful in treating type 1 diabetes, the underlying autoimmune condition is still there. Because transplanted cells come from cadaver donors, people who have islet cell transplants must take immune-suppressing drugs to prevent rejection of the new cells. This puts people at risk of developing complications from the medication, and, over time, the immune system destroys the new islet cells.

Because of these issues, islet cell transplantation is generally reserved for people whose diabetes is very difficult to control or who no longer have an awareness of potentially dangerous low blood-sugar levels.

Julia Greenstein, vice president of Cure Therapies for JDRF (formerly the Juvenile Diabetes Research Institute), said the risks of islet cell transplantation currently outweigh the benefits for healthy people with type 1 diabetes.

That's where the BioHub comes in.

"The BioHub is like a nest that the islet cells will sit in and be protected and cared for," Inverardi said. "It's a transparent, flat structure about the size of a quarter. It's shaped so you can put the islet cells in it, and it's porous to allow [the islets to develop a new blood supply]."

The device is made of a silicone compound that's already in use for other medical conditions. "The BioHub is ... like an open frame, with about 95 percent air. The design keeps the islets from clumping together," said Ricordi, who added that this would likely translate to a need for fewer islet cells. And, he said, the design allows the researchers to add new components as they're developed and approved.

In the future, the BioHub might be in an even more natural container, such as a tied-off vein that would create a sac to hold the islet cells, Ricordi said. The advantage of a vein is that the blood supply is already there.

Initially, the researchers will implant the BioHub in the omental pouch, an area in the lining of the abdominal cavity that connects the stomach to other abdominal organs. Once there, the BioHub would sense changing blood-sugar levels and would release insulin when needed.

Inverardi said one of the biggest advantages to the BioHub is that researchers will easily be able to find the best site to transplant islet cells, because if a site doesn't work well, the device can be easily retrieved.

Inverardi and Ricordi both expect this phase to go well, and expect the BioHub with the transplanted islets to begin producing insulin.

Eventually, the researchers hope to develop and test immune suppression that is only in the area of the islet cells, instead of affecting the whole body. One possible way to accomplish this, Inverardi said, is to encapsulate the islet cells in a material that allows the cells to breathe and exchange insulin, but will repel any immune attack. At this point, there is no timeline scheduled for clinical trials of this portion of the BioHub.

The researchers also hope to find alternative sources for islet cells to use in the BioHub. Possible avenues of research include living, related donors; islet cells from pigs; and stem-cell-produced islets.

"We're excited about this research," Greenstein said. "This is an incremental step that indicates progress, but, until we get rid of the need for chronic immunosuppression, the use is limited to those with severe [low blood sugar] unawareness."

More information

Learn more about type 1 diabetes from the Diabetes Research Institute.

SOURCES: Camillo Ricordi, M.D., director, and Luca Inverardi, M.D., deputy director, translational research, Diabetes Research Institute, University of Miami; Julia Greenstein, Ph.D., vice president, Cure Therapies, JDRF, New York City


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. MSU plan would control deadly tsetse fly
2. New process would make anti-malarial drug less costly
3. How much would our health benefit from leaving the car at home?
4. Lowering the national ozone standard would significantly reduce mortality and morbidity
5. Reducing Ozone Limits Would Save Lives, Report States
6. NYC Ban on Super-Sized Sodas Would Cut Consumers Calories: Study
7. Expanding Access to Medicaid Would Save Lives: Study
8. Would sliding back to pre-PSA era cancel progress in prostate cancer?
9. What would happen without PSA testing?
10. 5 Steps Would Lower Preemie Rates in Richest Countries: Study
11. Banning Vaccine Preservative Would Hurt Kids in Poor Nations: Experts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mini-Organ Would Mimic Pancreas to Treat Type 1 Diabetes
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 2016 , ... US Sports Camps is proud to sponsor the Bay Area ... top non-profit leaders, ultimate organizations, and coaches from around the US. The theme for ... Program Director of Youth and Education, describes this year YUCC as “an important conversation ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
Breaking Medicine Technology: